BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 26934120)

  • 1. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant.
    Li T; Kong AN; Ma Z; Liu H; Liu P; Xiao Y; Jiang X; Wang L
    Oncotarget; 2016 Apr; 7(15):20236-48. PubMed ID: 26934120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
    Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
    Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
    Li C; Guan X; Xue H; Wang P; Wang M; Gai X
    Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells.
    Han CY; Cho KB; Choi HS; Han HK; Kang KW
    Carcinogenesis; 2008 Sep; 29(9):1837-44. PubMed ID: 18390843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer.
    Zhang E; Liu J; Shi L; Guo X; Liang Z; Zuo J; Xu H; Wang H; Shu X; Huang S; Zhang S; Kang X; Zhen Y
    Life Sci; 2019 Dec; 238():116938. PubMed ID: 31593704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1.
    Xie Y; Ke S; Ouyang N; He J; Xie W; Bedford MT; Tian Y
    J Biol Chem; 2009 Apr; 284(14):9199-205. PubMed ID: 19144646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
    Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
    Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
    Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
    J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway.
    Wang W; Zou L; Zhou D; Zhou Z; Tang F; Xu Z; Liu X
    Mol Carcinog; 2016 Sep; 55(9):1329-42. PubMed ID: 26293643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
    Qi X; Chang Z; Song J; Gao G; Shen Z
    Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
    Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
    Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
    David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
    Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells.
    Hien TT; Kim HG; Han EH; Kang KW; Jeong HG
    Mol Nutr Food Res; 2010 Jul; 54(7):918-28. PubMed ID: 20077420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells.
    Li Y; Sun Y; Tang T; Niu Y; Li X; Xie M; Jin H; Mei Q
    J Ethnopharmacol; 2019 Mar; 232():47-54. PubMed ID: 30552993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
    Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
    Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.